COTI was formed in 1999 with the intention of marketing its drug discovery and
molecular screening technology to pharmaceutical and biotechnology companies. Other
commercial opportunities that were identified included software design and support
services for pharmaceutical companies looking to build in silico drug discovery in house.
However, entrenched methodologies in the industry and internally developed drug development technologies within pharmaceutical
companies made market penetration difficult. In 2000, COTI turned to developing its own molecule
discoveries into drugs. Currently, three drugs have been patented, and two have been synthesized
and tested in vitro and in vivo and several others are awaiting funds in order to patent
and develop the compounds.